ℹ️ Compiled from public regulatory records · Last regulator revision: November 4, 2025

Cefprozil

Second-Generation Cephalosporins

CA Health CanadaUS FDA

Drug class: Second-Generation Cephalosporins
Availability: Prescription only
Routes: Oral
Markets covered: 2
Products on record: 8
FDA reports (12 mo): 38

J01DCSecond-Generation Cephalosporins

Overview

Plain-language summary, compiled from the cited regulatory records

Cefprozil is an antibiotic medication belonging to the second-generation cephalosporin class of drugs [1]. It is approved for treating mild to moderate infections caused by specific bacteria [1]. These infections include upper respiratory tract conditions such as pharyngitis and tonsillitis, when caused by Streptococcus pyogenes [1].

In the market, cefprozil is available under various brand names. In the past 12 months, there have been 38 adverse event reports associated with cefprozil [2].

This is not medical advice. Consult a qualified healthcare professional.

Regulatory status by market

Market	Regulator	Products	Last revision
CA Canada	Health Canada	7	November 4, 2025
US United States	FDA	1	October 10, 2025

CACanada· Health Canada

7 products

Uses

CAOfficial regulatory label· revised March 22, 2025[1]

AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS ........................................................................................................ 4 WARNINGS AND PRECAUTIONS .......................................................................................
4 ADVERSE REACTIONS ......................................................................................................... 6 DRUG INTERACTIONS .........................................................................................................
8 DOSAGE AND ADMINISTRATION ..................................................................................... 8 OVERDOSAGE........................................................................................................................
9 ACTION AND CLINICAL PHARMACOLOGY. ................................................................... 9 STORAGE AND STABILITY .............................................................................................. 11 DOSAGE FORMS, COMPOSITION AND PACKAGING ..................................................

USUnited States· FDA

1 product

Uses

USOfficial regulatory label· revised October 10, 2025[2]

INDICATIONS AND USAGE
Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes .
NOTE:
The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present.
Otitis Media:
Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). ) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor.

Drug interactions

Known interactions involving Cefprozil. Select one for details. This list is informational and not a complete interaction checker.

Vibrio Cholerae CVD 103-HGR Strain Live Antigen Amikacin Anisindione Balsalazide Bumetanide Chloramphenicol Dicumarol Entecavir Estradiol Ethacrynate Ethinyl Estradiol Furosemide Gentamicin Givosiran Kanamycin Lactobacillus Acidophilus Mestranol Mycophenolate Mofetil Mycophenolic Acid Neomycin Netilmicin Nimodipine Pemetrexed Picosulfurate Plazomicin Probenecid Streptomycin Tobramycin Torsemide Warfarin Acetaminophen Albuterol Alendronate Amlodipine Amoxicillin Aspirin Atomoxetine Atorvastatin Azithromycin Budesonide Bupropion Cefazolin Cefdinir Cefoxitin Ceftriaxone Cefuroxime Celecoxib Cephalexin Cetirizine Chlorhexidine Cimetidine Ciprofloxacin Citalopram Clarithromycin Clopidogrel Clotrimazole Cyclobenzaprine Desloratadine Diazepam Digoxin Diltiazem Doxazosin Erythromycin Etodolac Ezetimibe Famotidine Felodipine Fentanyl Fexofenadine Fluconazole Fluoxetine Fluticasone Folic Acid Fosinopril Gabapentin Gemfibrozil Hydrochlorothiazide Hydrocortisone Ibuprofen Lansoprazole Latanoprost Levothyroxine Lincomycin Lisinopril Loratadine Lorazepam Lovastatin Metformin Methocarbamol Methylphenidate Methylprednisolone Metoprolol Montelukast Moxifloxacin Nadolol Naproxen Niacin Nifedipine Nitroglycerin Nizatidine Nortriptyline Ofloxacin Omeprazole Oxybutynin Pantoprazole Paroxetine Potassium Chloride Prednisolone Prednisone Promethazine Quetiapine Rabeprazole Ranitidine Rofecoxib Sertraline Simvastatin Spironolactone Tamsulosin Tegaserod Telithromycin Triamcinolone Valsartan Venlafaxine Zafirlukast Zolpidem

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]Health Canada (DPD) · 02347253 · revised March 22, 2025
[2]FDA DailyMed · 14527f4a-ce99-44… · revised October 10, 2025 [PDF]
[3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.